CD20 underexpression
|
NHL
|
CD20 underexpression
|
NHL
|
mosunetuzumab Resistant: C3 – Early Trials
|
mosunetuzumab Resistant: C3 – Early Trials
|
CD20 underexpression
|
Multiple Myeloma
|
CD20 underexpression
|
Multiple Myeloma
|
lenalidomide Resistant: D – Preclinical
|
lenalidomide Resistant: D – Preclinical
|
CD20 underexpression
|
Multiple Myeloma
|
CD20 underexpression
|
Multiple Myeloma
|
elotuzumab Resistant: D – Preclinical
|
elotuzumab Resistant: D – Preclinical
|